IGF2 and neoplasm: Cell 3 and its primary tumor 3 presented 28 genomic alterations in common (Table S1), including gains of 4q12 (PDGFRA), an amplification of 11p15.5 (H19 and IGF2 genes), and a loss of 6p25.3 (DUSP22).